GHRP-6 vs Hexarelin
Hunger-inducing GH secretagogue vs most potent GHRP with cardioprotective effects — comparing two classic growth hormone releasing peptides.
Last updated: 2026-03-08
Quick Comparison Table
| Category | GHRP-6 | Hexarelin |
|---|---|---|
| Potency (GH Release) | High | Highest among GHRPs |
| Appetite Stimulation | Very strong (major side effect) | Moderate |
| Cortisol Elevation | Moderate | Moderate-high |
| Prolactin Elevation | Moderate | Moderate |
| Unique Property | Intense hunger stimulation | Cardioprotective (CD36 receptor) |
| Desensitisation | Moderate (weeks-months) | Significant (4-8 weeks) |
| Administration | SC injection 2-3x daily | SC injection 2-3x daily |
| Ideal Use Case | GH + appetite stimulation (underweight/catabolic) | Maximum GH + cardiac research |
Mechanism of Action
GHRP-6
GHRP-6 Mechanism:
GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂) is a synthetic hexapeptide GH secretagogue.
Key actions: 1. **GHS-R1a activation** — Potent ghrelin receptor agonism, stimulating GH release 2. **Intense appetite stimulation** — The strongest appetite effect among GHRPs, driven by ghrelin receptor activation in the hypothalamus and vagal afferents 3. **Cortisol/prolactin elevation** — Moderate increases at GH-releasing doses 4. **Gastric motility** — Increases gastric acid secretion and gut motility 5. **IGF-1 elevation** — Secondary to GH release
GHRP-6's intense appetite stimulation makes it both a limitation (for body composition goals) and an advantage (for catabolic or underweight patients needing caloric intake support).
Hexarelin
Hexarelin Mechanism:
Hexarelin (His-D-2-Methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂) is the most potent peptide GH secretagogue.
Key actions: 1. **GHS-R1a activation** — Most potent GH release among all GHRPs 2. **CD36 receptor activation** — Unique cardioprotective pathway independent of GH 3. **Cardiac remodelling** — Reduces fibrosis and hypertrophy in heart failure models 4. **Cortisol/prolactin elevation** — Moderate-high at effective doses 5. **Desensitisation** — GH response diminishes 50-80% after 4-8 weeks of continuous use
Hexarelin's CD36-mediated cardioprotection is unique among GHRPs and represents a distinct therapeutic potential beyond GH release.
Clinical Trial Evidence
GHRP-6 Clinical Studies
Participants: 30
Duration: Acute
GHRP-6 at 1mcg/kg IV produced peak GH of ~40-55 ng/mL. Consistent, robust GH release.
Statistically significant
Participants: 18
Duration: 7 days
GHRP-6 increased caloric intake by 20-30% within 30 minutes of injection. Most intense appetite effect of any GHRP.
Statistically significant
Participants: 15
Duration: 12 weeks
GHRP-6 improved body weight and lean mass in HIV wasting syndrome. Appetite stimulation was therapeutically beneficial.
Statistically significant
Participants: 80
Duration: Acute
GHRP-6 stimulation test validated for GH deficiency diagnosis with good sensitivity and specificity.
Statistically significant
Participants: 20
Duration: Single dose
GHRP-6 increased gastric acid secretion and accelerated gastric emptying via vagal and ghrelin receptor mechanisms.
Not statistically significant
Hexarelin Clinical Studies
Participants: 24
Duration: Acute
Hexarelin at 1mcg/kg IV produced peak GH of ~65-80 ng/mL — highest among all peptide secretagogues tested.
Statistically significant
Participants: 0
Duration: 4 weeks
Hexarelin reduced infarct size by 35% and improved cardiac function post-MI via CD36 receptor activation. Independent of GH.
Statistically significant
Participants: 16
Duration: 8 weeks
GH response to Hexarelin decreased by 50-80% after 4-8 weeks of continuous use. Desensitisation confirmed.
Not statistically significant
Participants: 0
Duration: In vivo
Hexarelin reduced cardiac fibrosis and hypertrophy in pressure-overload heart failure model. Anti-fibrotic effect via CD36.
Statistically significant
Participants: 0
Duration: In vivo (mice)
Hexarelin reduced atherosclerotic plaque formation by 40% in ApoE-knockout mice. Anti-inflammatory lipid handling via CD36.
Statistically significant
Benefits Comparison
GHRP-6 Unique Benefits
- Intense appetite stimulation (therapeutic in wasting)
- Reliable GH release
- Validated GH deficiency diagnostic
- Less desensitisation than Hexarelin
- Gastric motility enhancement
Shared Benefits
- GH secretagogue activity
- Cortisol/prolactin elevation
- Compatible with GHRH analogues
- Injectable peptides with established pharmacology
Hexarelin Unique Benefits
- Most potent GH release among GHRPs
- Unique cardioprotective activity (CD36)
- Anti-fibrotic cardiac effects
- Anti-atherosclerotic properties
- Dual mechanism (GH + cardiac)
Research & Evidence
GHRP-6 Research
GHRP-6 is well-studied as a GH secretagogue and diagnostic tool. Its appetite-stimulating properties have been explored for wasting conditions. However, it has not progressed to therapeutic approval due to non-selectivity.
Hexarelin Research
Hexarelin's cardioprotective effects via CD36 represent a unique research avenue beyond GH secretion. This has generated sustained research interest despite the desensitisation limitation. No other GHRP has this cardiac profile.
Head-to-Head Analysis
Classic GHRP Comparison:
Both are "first-generation" GHRPs with broad receptor activity.
GH Release: Hexarelin is the most potent GHRP for acute GH release — approximately 30-50% more GH than GHRP-6 at equivalent doses.
Key Differentiator — Appetite: GHRP-6 causes intense, almost immediate hunger after injection. Hexarelin produces moderate appetite stimulation. For patients seeking weight gain, GHRP-6's hunger effect is beneficial; for body composition, it's a significant limitation.
Key Differentiator — Desensitisation: Hexarelin desensitises significantly faster (4-8 weeks) than GHRP-6 (weeks-months), requiring cycling. This limits Hexarelin's use for sustained GH elevation.
Key Differentiator — Cardioprotection: Hexarelin's CD36 activation is unique and not shared by GHRP-6 or any other GHRP.
Protocol Comparison
GHRP-6 Protocol
GHRP-6 Theoretical Protocols:
Dosing: 100-300mcg SC, 2-3x daily. Timing: On empty stomach (30 min before meals for maximal GH + appetite effect). Duration: Can be used continuously for weeks-months with gradual desensitisation.
⚠️ Warning: Intense hunger begins within 15-20 minutes of injection.
Hexarelin Protocol
Hexarelin Theoretical Protocols:
Dosing: 100-200mcg SC, 1-3x daily. Cycling Required: 4-8 weeks on, 4-8 weeks off due to desensitisation. Combination: Often used with CJC-1295 for synergistic GH release.
⚠️ Note: GH response diminishes significantly after 4-8 weeks of continuous use.
Safety Profiles
GHRP-6 Safety
GHRP-6 Safety:
Common: Intense hunger (20-30 minutes post-injection), water retention, cortisol elevation, prolactin increase. Gastric discomfort possible.
Main practical concern: Uncontrollable appetite may lead to weight gain rather than body recomposition.
Hexarelin Safety
Hexarelin Safety:
Common: Moderate appetite increase, cortisol and prolactin elevation, water retention.
Desensitisation is the primary safety/efficacy concern — requiring cycling protocols.
Cardioprotective effects suggest a favourable cardiac safety profile.
The Verdict
GHRP-6 and Hexarelin serve different niches within the GHRP family. Hexarelin wins on raw GH-releasing potency and offers unique cardioprotective benefits via CD36, but its rapid desensitisation limits sustained use. GHRP-6's intense appetite stimulation is either its greatest weakness (body composition goals) or greatest strength (wasting conditions). For maximum acute GH release and cardiac research, Hexarelin is preferred. For sustained GH support with appetite stimulation, GHRP-6 is more practical. Most researchers have migrated toward Ipamorelin for its cleaner profile.
Frequently Asked Questions
Conclusion
GHRP-6 and Hexarelin are classic first-generation GHRPs with distinct profiles — GHRP-6 for appetite-dependent applications and sustained use, Hexarelin for maximum GH potency and unique cardiac research. Both have been largely superseded by Ipamorelin for general GH research due to its superior selectivity, but each retains a niche: GHRP-6 for wasting conditions where appetite is therapeutic, and Hexarelin for cardioprotective research that no other GHRP can address.
Medical Disclaimer
The information provided in this comparison is for educational and research purposes only. Neither GHRP-6 nor Hexarelin is approved for human therapeutic use by the MHRA, EMA, or FDA. This content does not constitute medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement.